4D pharma to Present Additional Data from its completed Phase II Study of Blautix for the Treatment of IBS-C and IBS-D at Digestive Disease Week (DDW) 2021. The Company will host a webcast event on May 25 at 17:00 BST (12:00 EDT) to discuss the additional data and how it relates to the current IBS treatment landscape.
4D pharma announces a collaboration with Parkinson’s UK, a non-profit organization focused on advancing the understanding of Parkinson’s disease and improving treatments, to establish a Patient Advisory Board
4D pharma CEO, Duncan Peyton, and CSO, Alex Stevenson, will participate in a fireside chat at the Jefferies Microbiome-Based Therapeutics Summit on Thursday, April 22, 2021 at 1:00 p.m. BST (8:00 a.m. ET).